Boston Scientific to stop heart device sales, not seek new approvals

Boston Scientific to eliminate jobs after heart device discontinues

The company, with a huge Minnesota cardiology division, is cutting its Acurate devices, citing conversations with regulators.

Boston Scientific to stop heart device sales, not seek new approvals

(Reuters) -Boston Scientific said on Wednesday it has stopped global sales of its heart device and will not seek approval in geographies it is not yet available due to increased clinical and regulatory requirements. Shares of the device maker fell 1.5% to $104.57 in premarket trading. The devices, called transcatheter aortic valve replacement (TAVR), had obtained the European Union’s CE-mark and were sold under the brands Acurate Prime and Acura…

Boston Scientific stock falls as ACURATE is pulled from market

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves after regulatory feedback. Read more here.

Boston Scientific to stop heart device sales, not seek new approvals - Regional Media News

(Reuters) -Boston Scientific said on Wednesday it has stopped global sales of its heart device and will not seek approval in geographies it is not yet available due to increased clinical and regulatory requirements. Shares of the device maker fell 1.5% to $104.57 in premarket trading. The devices, called transcatheter aortic valve replacement (TAVR), had obtained the European Union’s CE-mark and were sold under the brands Acurate Prime and Acura…

Atrial fibrillation: an increasing condition Atrial fibrillation (AF) affects approximately 1.5–2% of the global population.1 In Europe, more than six million people live with this arrhythmia, and it is estimated that its prevalence will double over the next 50 years as a result of population ageing. In Spain, the prevalence of AF in over 40 years of age exceeds 4%, which means that more than one million people could be affected, according to cu…